Amicus Therapeutics

CIBRA Capital disclosed a purchase of 1,476,861 shares of Amicus Therapeutics in its April 24 SEC filing, an estimated $21.17 million trade based on Q1 average pricing. Post-trade the fund holds 1,687,661 shares valued at $24.40 million, representing 11.78% of its reportable AUM and a 10.2% change in AUM. The buy appears to be merger arbitrage ahead of BioMarin’s $14.50-per-share offer for Amicus; if the deal completes CIBRA would earn a modest spread, but failure of the transaction could trigger a sharp share decline. » Más en finance.yahoo.com

Amicus Therapeutics shares climbed to a 52-week high of $14.46 after rising 115.1% over the past year. Investors point to a strong gross margin of 88.5% and a market capitalization of $4.54 billion. Shareholders narrowly approved the takeover by BioMarin, while Jefferies downgraded its rating to "Hold." Amicus will present new data on treatments for Fabry and Pompe diseases at the WORLDSymposium 2026. » Más en de.investing.com

Shares of Amicus Therapeutics rose to $14.39, marking a 52-week high, driven by a 58.4% gain for the year and a 73% rise over six months. Shareholders approved the acquisition by BioMarin, which values Amicus at $14.50 per share and about $4.8 billion. The company reports a gross profit margin of 88.5% and revenue growth of 20% and will present new study data at the WORLDSymposium 2026; some analysts have cut their ratings and price targets to the takeover price. » Más en de.investing.com